Literature DB >> 15590954

Cancer of the ovary.

Stephen A Cannistra1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15590954     DOI： 10.1056/NEJMra041842

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  619 in total

1.  Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer.

Authors:  Nicole D Fleming; Robert L Coleman; Celestine Tung; Shannon N Westin; Wei Hu; Yunjie Sun; Priya Bhosale; Mark F Munsell; Anil K Sood
Journal:  Gynecol Oncol       Date:  2017-08-01       Impact factor: 5.482

2.  Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts.

Authors:  Sara Previdi; Anastasia Malek; Veronica Albertini; Cristina Riva; Carlo Capella; Massimo Broggini; Giuseppina M Carbone; Jurgen Rohr; Carlo V Catapano
Journal:  Gynecol Oncol       Date:  2010-05-08       Impact factor: 5.482

3.  Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy.

Authors:  Seiya Sato; Hiroaki Itamochi
Journal:  Ther Adv Med Oncol       Date:  2014-11       Impact factor: 8.168

Review 4.  Modern trends into the epidemiology and screening of ovarian cancer. Genetic substrate of the sporadic form.

Authors:  Maria Koutsaki; Apostolos Zaravinos; Demetrios A Spandidos
Journal:  Pathol Oncol Res       Date:  2011-12-09       Impact factor: 3.201

5.  Expression of the Wnt antagonist DKK3 is frequently suppressed in sporadic epithelial ovarian cancer.

Authors:  An You; Emmanouil Fokas; Lin-Fang Wang; Haitao He; Beate Kleb; Dieter Niederacher; Rita Engenhart-Cabillic; Han-Xiang An
Journal:  J Cancer Res Clin Oncol       Date:  2010-06-09       Impact factor: 4.553

6.  Over-expression of miR-31 or loss of KCNMA1 leads to increased cisplatin resistance in ovarian cancer cells.

Authors:  Priya Samuel; Ryan Charles Pink; Daniel Paul Caley; James Michael Stevenson Currie; Susan Ann Brooks; David Raul Francisco Carter
Journal:  Tumour Biol       Date:  2015-09-19

Review 7.  Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer.

Authors:  Bayley A Jones; Sooryanarayana Varambally; Rebecca C Arend
Journal:  Mol Cancer Ther       Date:  2018-03       Impact factor: 6.261

8.  The association between MTHFR C677T polymorphism and ovarian cancer risk: a meta-analysis of 18,628 individuals.

Authors:  Chengbin Ma; Yan Liu; Wenying Zhang; Ping Liu
Journal:  Mol Biol Rep       Date:  2013-01-18       Impact factor: 2.316

Review 9.  Immunotherapy in ovarian cancer.

Authors:  Gina M Mantia-Smaldone; Bradley Corr; Christina S Chu
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

10.  Comparison of Platinum-based Neoadjuvant Chemotherapy and Primary Debulking Surgery in Patients with Advanced Ovarian Cancer.

Authors:  Manizheh Sayyah-Melli; Gita Kashi Zonoozi; Shahryar Hashemzadeh; Ali Esfahani; Elaheh Ouladehsahebmadarek; Mehry Jafary Shobeiry; Parvin Mostafa Garabaghi; Azhough Ramin
Journal:  J Obstet Gynaecol India       Date:  2013-08-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.